Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.

Nicolino Ruperto, Daniel J. Lovell, Tracy Li, Flavio Sztajnbok, Claudia Goldenstein-Schainberg, Morton Scheinberg, Inmaculada Calvo Penades, Michael Fischbach, Javier Orozco Alcala, Philip J. Hashkes, Christine Hom, Lawrence Jung, Loredana Lepore, Sheila Oliveira, Carol Wallace, Maria Alessio, Pierre Quartier, Elisabetta Cortis, Anne Eberhard, Gabriele SimoniniIrene Lemelle, Elizabeth Candell Chalom, Leonard H. Sigal, Alan Block, Allison Covucci, Marleen Nys, Alberto Martini, Edward H. Giannini, Rheumatology International Trials Organisation (PRINTO) Paediatric Rheumatology International Trials Organisation (PRINTO), Rheumatology Collaborative Study Group (PRCSG) Pediatric Rheumatology Collaborative Study Group (PRCSG)

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

To assess health-related quality of life (HRQOL) in abatacept-treated children/adolescents with juvenile idiopathic arthritis (JIA). In this phase III, double-blind, placebo-controlled trial, subjects with active polyarticular course JIA and an inadequate response/intolerance to ≥1 disease-modifying antirheumatic drug (including biologics) received abatacept 10 mg/kg plus methotrexate (MTX) during the 4-month open-label period (period A). Subjects achieving the American College of Rheumatology Pediatric 30 criteria for improvement (defined "responders") were randomized to abatacept or placebo (plus MTX) in the 6-month double-blind withdrawal period (period B). HRQOL assessments included 15 Child Health Questionnaire (CHQ) health concepts plus the physical (PhS) and psychosocial summary scores (PsS), pain (100-mm visual analog scale), the Children's Sleep Habits Questionnaire, and a daily activity participation questionnaire. A total of 190 subjects from period A and 122 from period B were eligible for analysis. In period A, there were substantial improvements across all of the CHQ domains (greatest improvement was in pain/discomfort) and the PhS (8.3 units) and PsS (4.3 units) with abatacept. At the end of period B, abatacept-treated subjects had greater improvements versus placebo in all domains (except behavior) and both summary scores. Similar improvement patterns were seen with pain and sleep. For participation in daily activities, an additional 2.6 school days/month and 2.3 parents' usual activity days/month were gained in period A responders with abatacept, and further gains were made in period B (1.9 versus 0.9 [P = 0.033] and 0.2 versus -1.3 [P = 0.109] school days/month and parents' usual activity days/month, respectively, in abatacept- versus placebo-treated subjects). Improvements in HRQOL were observed with abatacept, providing real-life tangible benefits to children with JIA and their parents/caregivers.

Original languageEnglish
Pages (from-to)1542-1551
Number of pages10
JournalArthritis Care and Research
Volume62
Issue number11
Publication statusPublished - Nov 2010

Fingerprint

Juvenile Arthritis
Sleep
Quality of Life
Pain
Placebos
Parents
Methotrexate
Physical Phenomena
Antirheumatic Agents
Abatacept
Biological Products
Visual Analog Scale
Caregivers
Habits
Pediatrics
Surveys and Questionnaires
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ruperto, N., Lovell, D. J., Li, T., Sztajnbok, F., Goldenstein-Schainberg, C., Scheinberg, M., ... Pediatric Rheumatology Collaborative Study Group (PRCSG), R. C. S. G. PRCSG. (2010). Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care and Research, 62(11), 1542-1551.

Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. / Ruperto, Nicolino; Lovell, Daniel J.; Li, Tracy; Sztajnbok, Flavio; Goldenstein-Schainberg, Claudia; Scheinberg, Morton; Penades, Inmaculada Calvo; Fischbach, Michael; Alcala, Javier Orozco; Hashkes, Philip J.; Hom, Christine; Jung, Lawrence; Lepore, Loredana; Oliveira, Sheila; Wallace, Carol; Alessio, Maria; Quartier, Pierre; Cortis, Elisabetta; Eberhard, Anne; Simonini, Gabriele; Lemelle, Irene; Chalom, Elizabeth Candell; Sigal, Leonard H.; Block, Alan; Covucci, Allison; Nys, Marleen; Martini, Alberto; Giannini, Edward H.; Paediatric Rheumatology International Trials Organisation (PRINTO), Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG), Rheumatology Collaborative Study Group (PRCSG).

In: Arthritis Care and Research, Vol. 62, No. 11, 11.2010, p. 1542-1551.

Research output: Contribution to journalArticle

Ruperto, N, Lovell, DJ, Li, T, Sztajnbok, F, Goldenstein-Schainberg, C, Scheinberg, M, Penades, IC, Fischbach, M, Alcala, JO, Hashkes, PJ, Hom, C, Jung, L, Lepore, L, Oliveira, S, Wallace, C, Alessio, M, Quartier, P, Cortis, E, Eberhard, A, Simonini, G, Lemelle, I, Chalom, EC, Sigal, LH, Block, A, Covucci, A, Nys, M, Martini, A, Giannini, EH, Paediatric Rheumatology International Trials Organisation (PRINTO), RITOPRINTO & Pediatric Rheumatology Collaborative Study Group (PRCSG), RCSGPRCSG 2010, 'Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.', Arthritis Care and Research, vol. 62, no. 11, pp. 1542-1551.
Ruperto, Nicolino ; Lovell, Daniel J. ; Li, Tracy ; Sztajnbok, Flavio ; Goldenstein-Schainberg, Claudia ; Scheinberg, Morton ; Penades, Inmaculada Calvo ; Fischbach, Michael ; Alcala, Javier Orozco ; Hashkes, Philip J. ; Hom, Christine ; Jung, Lawrence ; Lepore, Loredana ; Oliveira, Sheila ; Wallace, Carol ; Alessio, Maria ; Quartier, Pierre ; Cortis, Elisabetta ; Eberhard, Anne ; Simonini, Gabriele ; Lemelle, Irene ; Chalom, Elizabeth Candell ; Sigal, Leonard H. ; Block, Alan ; Covucci, Allison ; Nys, Marleen ; Martini, Alberto ; Giannini, Edward H. ; Paediatric Rheumatology International Trials Organisation (PRINTO), Rheumatology International Trials Organisation (PRINTO) ; Pediatric Rheumatology Collaborative Study Group (PRCSG), Rheumatology Collaborative Study Group (PRCSG). / Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. In: Arthritis Care and Research. 2010 ; Vol. 62, No. 11. pp. 1542-1551.
@article{1147a66074294610b1be6fd557ec3a1e,
title = "Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.",
abstract = "To assess health-related quality of life (HRQOL) in abatacept-treated children/adolescents with juvenile idiopathic arthritis (JIA). In this phase III, double-blind, placebo-controlled trial, subjects with active polyarticular course JIA and an inadequate response/intolerance to ≥1 disease-modifying antirheumatic drug (including biologics) received abatacept 10 mg/kg plus methotrexate (MTX) during the 4-month open-label period (period A). Subjects achieving the American College of Rheumatology Pediatric 30 criteria for improvement (defined {"}responders{"}) were randomized to abatacept or placebo (plus MTX) in the 6-month double-blind withdrawal period (period B). HRQOL assessments included 15 Child Health Questionnaire (CHQ) health concepts plus the physical (PhS) and psychosocial summary scores (PsS), pain (100-mm visual analog scale), the Children's Sleep Habits Questionnaire, and a daily activity participation questionnaire. A total of 190 subjects from period A and 122 from period B were eligible for analysis. In period A, there were substantial improvements across all of the CHQ domains (greatest improvement was in pain/discomfort) and the PhS (8.3 units) and PsS (4.3 units) with abatacept. At the end of period B, abatacept-treated subjects had greater improvements versus placebo in all domains (except behavior) and both summary scores. Similar improvement patterns were seen with pain and sleep. For participation in daily activities, an additional 2.6 school days/month and 2.3 parents' usual activity days/month were gained in period A responders with abatacept, and further gains were made in period B (1.9 versus 0.9 [P = 0.033] and 0.2 versus -1.3 [P = 0.109] school days/month and parents' usual activity days/month, respectively, in abatacept- versus placebo-treated subjects). Improvements in HRQOL were observed with abatacept, providing real-life tangible benefits to children with JIA and their parents/caregivers.",
author = "Nicolino Ruperto and Lovell, {Daniel J.} and Tracy Li and Flavio Sztajnbok and Claudia Goldenstein-Schainberg and Morton Scheinberg and Penades, {Inmaculada Calvo} and Michael Fischbach and Alcala, {Javier Orozco} and Hashkes, {Philip J.} and Christine Hom and Lawrence Jung and Loredana Lepore and Sheila Oliveira and Carol Wallace and Maria Alessio and Pierre Quartier and Elisabetta Cortis and Anne Eberhard and Gabriele Simonini and Irene Lemelle and Chalom, {Elizabeth Candell} and Sigal, {Leonard H.} and Alan Block and Allison Covucci and Marleen Nys and Alberto Martini and Giannini, {Edward H.} and {Paediatric Rheumatology International Trials Organisation (PRINTO)}, {Rheumatology International Trials Organisation (PRINTO)} and {Pediatric Rheumatology Collaborative Study Group (PRCSG)}, {Rheumatology Collaborative Study Group (PRCSG)}",
year = "2010",
month = "11",
language = "English",
volume = "62",
pages = "1542--1551",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.

AU - Ruperto, Nicolino

AU - Lovell, Daniel J.

AU - Li, Tracy

AU - Sztajnbok, Flavio

AU - Goldenstein-Schainberg, Claudia

AU - Scheinberg, Morton

AU - Penades, Inmaculada Calvo

AU - Fischbach, Michael

AU - Alcala, Javier Orozco

AU - Hashkes, Philip J.

AU - Hom, Christine

AU - Jung, Lawrence

AU - Lepore, Loredana

AU - Oliveira, Sheila

AU - Wallace, Carol

AU - Alessio, Maria

AU - Quartier, Pierre

AU - Cortis, Elisabetta

AU - Eberhard, Anne

AU - Simonini, Gabriele

AU - Lemelle, Irene

AU - Chalom, Elizabeth Candell

AU - Sigal, Leonard H.

AU - Block, Alan

AU - Covucci, Allison

AU - Nys, Marleen

AU - Martini, Alberto

AU - Giannini, Edward H.

AU - Paediatric Rheumatology International Trials Organisation (PRINTO), Rheumatology International Trials Organisation (PRINTO)

AU - Pediatric Rheumatology Collaborative Study Group (PRCSG), Rheumatology Collaborative Study Group (PRCSG)

PY - 2010/11

Y1 - 2010/11

N2 - To assess health-related quality of life (HRQOL) in abatacept-treated children/adolescents with juvenile idiopathic arthritis (JIA). In this phase III, double-blind, placebo-controlled trial, subjects with active polyarticular course JIA and an inadequate response/intolerance to ≥1 disease-modifying antirheumatic drug (including biologics) received abatacept 10 mg/kg plus methotrexate (MTX) during the 4-month open-label period (period A). Subjects achieving the American College of Rheumatology Pediatric 30 criteria for improvement (defined "responders") were randomized to abatacept or placebo (plus MTX) in the 6-month double-blind withdrawal period (period B). HRQOL assessments included 15 Child Health Questionnaire (CHQ) health concepts plus the physical (PhS) and psychosocial summary scores (PsS), pain (100-mm visual analog scale), the Children's Sleep Habits Questionnaire, and a daily activity participation questionnaire. A total of 190 subjects from period A and 122 from period B were eligible for analysis. In period A, there were substantial improvements across all of the CHQ domains (greatest improvement was in pain/discomfort) and the PhS (8.3 units) and PsS (4.3 units) with abatacept. At the end of period B, abatacept-treated subjects had greater improvements versus placebo in all domains (except behavior) and both summary scores. Similar improvement patterns were seen with pain and sleep. For participation in daily activities, an additional 2.6 school days/month and 2.3 parents' usual activity days/month were gained in period A responders with abatacept, and further gains were made in period B (1.9 versus 0.9 [P = 0.033] and 0.2 versus -1.3 [P = 0.109] school days/month and parents' usual activity days/month, respectively, in abatacept- versus placebo-treated subjects). Improvements in HRQOL were observed with abatacept, providing real-life tangible benefits to children with JIA and their parents/caregivers.

AB - To assess health-related quality of life (HRQOL) in abatacept-treated children/adolescents with juvenile idiopathic arthritis (JIA). In this phase III, double-blind, placebo-controlled trial, subjects with active polyarticular course JIA and an inadequate response/intolerance to ≥1 disease-modifying antirheumatic drug (including biologics) received abatacept 10 mg/kg plus methotrexate (MTX) during the 4-month open-label period (period A). Subjects achieving the American College of Rheumatology Pediatric 30 criteria for improvement (defined "responders") were randomized to abatacept or placebo (plus MTX) in the 6-month double-blind withdrawal period (period B). HRQOL assessments included 15 Child Health Questionnaire (CHQ) health concepts plus the physical (PhS) and psychosocial summary scores (PsS), pain (100-mm visual analog scale), the Children's Sleep Habits Questionnaire, and a daily activity participation questionnaire. A total of 190 subjects from period A and 122 from period B were eligible for analysis. In period A, there were substantial improvements across all of the CHQ domains (greatest improvement was in pain/discomfort) and the PhS (8.3 units) and PsS (4.3 units) with abatacept. At the end of period B, abatacept-treated subjects had greater improvements versus placebo in all domains (except behavior) and both summary scores. Similar improvement patterns were seen with pain and sleep. For participation in daily activities, an additional 2.6 school days/month and 2.3 parents' usual activity days/month were gained in period A responders with abatacept, and further gains were made in period B (1.9 versus 0.9 [P = 0.033] and 0.2 versus -1.3 [P = 0.109] school days/month and parents' usual activity days/month, respectively, in abatacept- versus placebo-treated subjects). Improvements in HRQOL were observed with abatacept, providing real-life tangible benefits to children with JIA and their parents/caregivers.

UR - http://www.scopus.com/inward/record.url?scp=79952063531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952063531&partnerID=8YFLogxK

M3 - Article

C2 - 20597110

AN - SCOPUS:79952063531

VL - 62

SP - 1542

EP - 1551

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 11

ER -